Abstract:Malignant hematopoietic cells gain metabolic plasticity, reorganize anabolic mechanisms to improve anabolic output and prevent oxidative damage, and bypass cell cycle checkpoints, eventually outcompeting normal hematopoietic cells. Current therapeutic strategies of acute myeloid leukemia (AML) are based on prognostic stratification that includes mutation profile as the closest surrogate to disease biology. Clinical efficacy of targeted therapies, e.g., agents targeting mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 or 2, are mostly limited to the presence of relevant mutations. Recent studies have not only demonstrated that specific mutations in AML create metabolic vulnerabilities but also highlighted the efficacy of targeting metabolic vulnerabilities in combination with inhibitors of these mutations. Therefore, delineating the functional relationships between genetic stratification, metabolic dependencies, and response to specific inhibitors of these vulnerabilities is crucial for identifying more effective therapeutic regimens, understanding resistance mechanisms, and identifying early response markers, ultimately improving the likelihood of cure. In addition, metabolic changes occurring in the tumor microenvironment have also been reported as therapeutic targets. The metabolic profiles of leukemia stem cells (LSCs) differ, and relapsed/refractory LSCs switch to alternative metabolic pathways, fueling oxidative phosphorylation (OXPHOS), rendering them therapeutically resistant. In this review, we discuss the role of cancer metabolic pathways that contribute to the metabolic plasticity of AML and confer resistance to standard therapy; we also highlight the latest promising developments in the field in translating these important findings to the clinic and discuss the tumor microenvironment that supports metabolic plasticity and interplay with AML cells.

The Role of Cholesterol Metabolism in Leukemia

The Role of Aberrant Metabolism in Cancer: Insights into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer

The role of cholesterol metabolism in tumor therapy, from bench to bed

Targeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implications

A Comprehensive Look at the Role of Hyperlipidemia in Promoting Colorectal Cancer Liver Metastasis

Cholesterol Metabolism: New Functions and Therapeutic Approaches in Cancer

Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities

The role of cholesterol metabolism in lung cancer

The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies

Role of de novo cholesterol synthesis enzymes in cancer

Metabolic regulation of the bone marrow microenvironment in leukemia

Cholesterol Metabolism in Tumor Microenvironment: Cancer Hallmarks and Therapeutic Opportunities

Cholesterol metabolism and tumor

Functional significance of cholesterol metabolism in cancer: from threat to treatment

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Cholesterol Metabolism in Drug‑resistant Cancer (Review).

Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Pro-gression

Enhancing Leukemia Treatment: The Role of Combined Therapies Based on Amino Acid Starvation

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

Dysregulation of cholesterol metabolism in cancer progression